Get started
Work

Treatment of Acute Myeloid Leukemia in the Community Setting

Year: 2024
Type: article
Abstract: The treatment landscape for acute myeloid leukemia (AML) is rapidly changing. Many new agents and lower-intensity regimens have been approved and can be safely used by hematologists and oncologists in both academic and community settings. The US Food and Drug Administration (FDA) held a virtual symposium on AML treatment in the community in November 2022. Several members of the FDA, along with practicing hematologists and oncologists in both academic and community settings, participated in the symposium. The goal of the symposium was to discuss challenges and opportunities in the treatment of patients with AML in community oncology settings. A summary of these discussions and key considerations are presented here.
DOI: 10.1093/oncolo/oyae051
Authors: Taha Al-Juhaishi, Servillano Dela Cruz, Rohan Gupta, Gina Keiffer, Vicki A Morrison, Iuliana Shapira, Ashley Woods, Kelly Norsworthy, Romeo Angelo de Claro, Marc R Theoret, Ravin Garg, Elizabeth Dianne Pulte
Institutions: University of Oklahoma Health Sciences Center, University of Oklahoma, Florida Cancer Specialists & Research Institute, Center for Cancer and Blood Disorders, Thomas Jefferson University, Sidney Kimmel Cancer Center, University of Minnesota, Hennepin County Medical Center, United States Food and Drug Administration, Center for Drug Evaluation and Research, Maryland Oncology Hematology
Language: English
Subfield: Hematology
Field: Medicine
Open Access status: gold
Estimated APC paid: $4,045
OpenAlex ID: W4401715051
FWCI:
Cites: 31
Cited by:
Related to: 10